In terms of therapeutic potency, PEGylated SSNs carrying electrostatically associated anti-EGFR siRNA significantly resisted the growth of the tumour and reduced its mass without any significant systemic toxicity in the animal model, reducing the dose of the siRNA applied and ultimately lowering the cost of treatment. The gene discussed is EGFR; the disease is neoplasm.